您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > Pirtobrutinib
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Pirtobrutinib
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Pirtobrutinib图片
规格:98%
分子量:479.43
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
Pirtobrutinib (LOXO-305) 是一种高选择性和非共价的下一代 BTK 抑制剂,可抑制多种 BTK C481 替代突变。Pirtobrutinib 导致小鼠异种移植模型中 BTK 依赖性淋巴瘤肿瘤的消退。Pirtobrutinib 对 BTK 的选择性也是 370 种其他激酶的 300 倍以上,并且在 1 μM 时对非激酶靶点没有明显的抑制作用。
货号:ajcx33874
CAS:2101700-15-4
分子式:C22H21F4N5O3
分子量:479.43
溶解度:DMSO : 50 mg/mL (104.29 mM; Need ultrasonic)
纯度:98%
存储:Store at -20°C
库存:现货

Background:

Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM[1].

Pirtobrutinib potently inhibits both wild-type BTK and BTK C481S-mediated kinase activity with nanomolar potency. Pirtobrutinib inhibits WT BTK (Y223) autophosphorylation with an IC50 of 3.68 nM. Pirtobrutinib inhibits BTK C481S Y223, C481T Y223, and C481R Y223 autophosphorylation with IC50s of 8.45, 7.23, and 11.73 nM, respectively[1].

[1]. Gomez E B , et al. Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations[J]. Blood, 2019, 134(Supplement_1):4644-4644.